ChasmConversations

Understanding the One Big Beautiful Bill Act (OBBBA) with Brian Fortune, Founder, Farragut Square Group

October 30, 2025

The One Big Beautiful Bill Act (OBBBA) has quickly become a focal point in healthcare policy discussions, raising questions about its potential impact and long-term implications. In this edition of ChasmConversations, Anil Joseph sat down with Brian Fortune, Founder of Farragut Square Group, to discuss the OBBBA and what it could mean for industry stakeholders.

About Brian Fortune

Brian Fortune is a healthcare legislative and regulatory consultant with more than 20 years of experience in the Washington, DC, healthcare policy sector. As Founder of Farragut Square Group, he advises institutional investors and corporate stakeholders on federal and state healthcare policy, helping them navigate complex regulatory environments.

To start, can you briefly explain what the One Big Beautiful Bill Act is, and why it matters for healthcare investors and operators right now?

The One Big Beautiful Bill Act was enacted on July 4, 2025, and makes several changes to Medicaid, impacting both enrollment and federal funding. Given the nascent nature of the law, many healthcare investors and operators are still parsing through how provisions could impact Medicaid businesses in terms of utilization and rate stability. 

Notably, the Medicaid provisions were designed to take effect gradually, with many of them not implemented until the late 2020s. Accordingly, much of the impact and state decision-making will likely occur in the medium term. However, the degree of pressure and the decision on how to respond will vary by state, with some opting for a more proactive approach to cutting spending, while others seek to delay provisions. 

Farragut has analyzed OBBBA by observing enrollment and state budgets. Why is that important in understanding the bill’s true market impact?

Two of the most important provisions of the bill directly affect state budgets by reducing the amount of federal matching dollars states can obtain through creative financing mechanisms. The first is limits on state-directed payments to providers from Medicaid managed care plans. The second is a gradual reduction in state provider taxes (except for nursing facility and intermediate care facility provider taxes) to a new ceiling of 3.5% from the current ceiling of 6% for expansion states. 

Other major policies affect Medicaid enrollment, the most important of which is a new work requirement for able-bodied adults in order to retain Medicaid eligibility. As this policy affects a significant number of Medicaid expansion enrollees, where the federal matching share is 90%, it will also affect the amount of federal dollars in a state’s Medicaid budget.

How do the new limits on state financing tools, such as provider taxes and State Directed Payments, affect the stability of Medicaid-dependent markets and providers?

Each state that faces a loss of federal matching dollars as OBBBA Medicaid policies begin to take effect in late 2027 and 2028 will have to adjust its service coverage and reimbursement, as all states must maintain balanced budgets. Each state will make those decisions in the context of its overall budget health and the magnitude of how the policy specifically affects it, as each state has different exposure to provider taxes and SDPs.

OBBBA is projected to cut federal Medicaid spending by roughly $1 trillion over ten years. What does the reduction signal for states, managed care plans, and investors? How should investors interpret that figure, as a risk, an opportunity, or both?

Although a useful talking point for advocates, Farragut does not take budget savings projections from the Congressional Budget Office (CBO) as gospel truth, as it is an integrated projection of savings off the federal baseline, and therefore every dollar removed in the first few years projects outsized baseline savings over 10 years, even though the actual specific reductions occurred only once. A second point is that roughly a third of that savings figure ($300B+) comes from the Medicaid work requirement. Still, few experts believe the policy will achieve anywhere near that impact, as providers, managed care, and states have an invested incentive to assist affected individuals in maintaining eligibility.

Moving forward, a more useful exercise is to look at each state’s exposure to provider tax and SDP reductions relative to their projected Medicaid budgets, as well as expanded or ancillary services that they might trim as a way to sidestep any major provider reimbursement cuts.

Farragut’s work often emphasizes state-level variation. Which types of states or markets do you expect to feel the greatest pressure? 

Given OBBBA’s intent to return to a pre-Affordable Care Act (ACA), statutorily accurate version of the Medicaid program, the Medicaid provisions of the law target expansion states. Of the 41 states (including DC) that adopted Medicaid expansion, 19 are governed by Republicans and 22 are governed by Democrats. While investors may focus on the eligibility and fiscal pressures on blue states, it is important to note that red states are implementing across-the-board (ATB) cuts well ahead of any OBBBA provisions going into effect. 

This is driven by various factors, including “right-sizing” Medicaid programs in states such as Idaho and internal conflict among Republican legislators in North Carolina. And states with budget constraints, such as Illinois and Indiana, are signaling that they are considering near-term ATB cuts to their Medicaid programs. So while the law’s intent was to shore up resources for Medicaid’s intended populations of children, long-term disabled, and the elderly, services to those traditionally protected populations are on the receiving end of these ATB cuts.

Farragut advises our clients to consider the diversity of the expansion states’ approaches. While investor concern is concentrated on states like California and New York, we would argue that those states took full advantage of flexibilities to expand services and eligible populations. In turn, they have more options for avoiding ATB cuts by reducing non-mandatory benefits and non-statutory populations. On the other hand, if an expansion state did not pursue waivers and other tools to enhance its Medicaid programs, they have less “fat to trim.”

Which provisions of OBBBA should investors watch most closely?

The primary provisions of concern for investors are the work requirement and provider taxes. Farragut reminds clients that many populations, including beneficiaries in active Substance Use Disorder (SUD) treatment, are exempt from the work and community engagement requirement, and the law intentionally times this provision for post-midterm implementation, at the earliest. States also have the option to apply for extensions, pushing implementation to January 1, 2029, if they successfully exhibit a “good faith” effort. 

In addition, if states do not receive extensions, it is likely they will pursue a legal challenge on the grounds that implementing the work requirement is an unfunded mandate. The law allocates a total of $200 million to states for implementation, which is woefully inadequate to cover the costs for the 41 states that must comply. For example, Georgia, the only state with an active work requirement, has spent over $54 million on its Pathways program from October 2021 to March 2025. According to the Government Accountability Office (GAO), nearly 88% of that spending came from the federal government. 

Skilled Nursing Facilities (SNFs) and Intermediate Care Facilities (ICFs) were carved out of provider taxes, concentrating the impact on hospital and Managed Care Organization (MCO) provider taxes in expansion states. The step-down from the 6% safe harbor threshold begins in 2027, FY 2028, and runs through FY 2032, or until affected provider taxes in expansion states reach the 3.5% threshold. Many expansion states do not have hospital or MCO provider taxes over 3.5%. Most do not have provider taxes above 5.5%. Should the provider tax provision not be ameliorated, states like Colorado, Connecticut, Oregon, Rhode Island, Vermont, and Virginia will need to address this decline in collections that start in 2026.

Given the gradual implementation of OBBBA through 2028, how is Farragut advising clients to prepare?

We advise clients on projected risks to both reimbursement and coverage, based on relevant state budget outlooks, a provider’s coverage mix of patients, and where they fall a continuum of risk in Medicaid, with more vulnerable populations being generally less at risk, and able-bodied adult populations being more so. We also see risk for ancillary services that are not core Medicaid benefits (e.g., adult dental) but are often added when state budgets are flush with cash and pulled back when budgets tighten.

Finally, what are the key indicators you’ll be watching as OBBBA takes effect, and what might signal that the market is adjusting faster or slower than expected?

The next two to three years will be very telling, as they will demonstrate how much some states may need to tighten eligibility and reimbursement before the adjustments to provider taxes. It will also be important from an advocacy standpoint, as any degree of pain on hospitals that serve a higher mix of Medicaid patients will be heard in Washington, and policy is always fluid. Washington is currently debating how painful the OBBBA policies will be and whether early implementation will amplify the pain. We won't be surprised if DC lawmakers try to ameliorate Medicaid policies before they take full effect.


ChasmConversations is an interview series presented by Chasm Partners featuring discussions with prominent entrepreneurs, investors, and leaders in today's healthcare industry. Access previous installments of the series here, and subscribe to receive future editions of ChasmConversations and related content directly in your inbox.

Brian Fortune
Founder of Farragut Square Group

Brian Fortune

Founder of Farragut Square Group
You may also like

Some of our clients

Aduro
Prealize
Remedy Partners
Trapelo by Intervention Insights
Healthloop
Antidote
Arcadia
AspenRx
Carecentrix
Clarify Health Solutions
Cohere Health
Connections Health Solutions
Contessa Health
Cortica
andros
Cricket Health
Crossix
eMindful
Genome Medical
Glooko
GNS Healthcare
Healthedge
Healthmyne
HealthPlanOne
iN2L
Independent Living Systems
Iodine Software
Kara Health
Kinsa
Lightship
MacroHealth
Maven Clinic
MDsave
MedAvail
MedVantx
Mequilibrium
Mt Sinai
NovuHealth
Nursegrid
Omada
One Digital
PierianDx
Propeller Health
Rethink Care
SCA
Shearwater Health
Solera
Syapse
Tia
TruHearing
Truveris
Verana Health
Vesta Healthcare
Vetsource
VisiQuate
Vitality
Zelis
Discovery Health Partners
Kalderos
Canvas Medical
Pocket Health
Onduo
Everyday Health
Groups
Post Acute Analytics
Uprise Health
CareXM
Spencer Health
TBH
MIC
Freespira
Owl Insights
Claritas Rx
Cleerly
Complion
Advocatia
Truepill
Sempre Health
Trellis Rx
Audacious Inquiry
Medable
Ontrak
LeanTaas
WPAS, Inc.
Brightline
NuvoAir
Belong Health
Carrum Health
Azara Healthcare
Phil
eVisit
Abarca
Calibrate
Helix
Valgenesis
AvaSure
Silversmith Capital Partners
BrainCheck
Vivalink
Elation Health
Oshi Health
ProJenX
Avalon
Cranemere
Solis Mammography
Main Street Health
Russell Street Ventures
Big Health
Healios
Almaden Genomics
Forge Health
Gather Health
Annexus Health
DotCom Therapy
Elucid
Wondr Health
Lyra
AMPS
Progeny Health
Nomi Health
Vita Health
Henry Schein One
Welcome Health
SeamlessMD
Workit Health
Soluta
Novum Health
Marquee Dental
Intermountain Ventures
BACA
WelbeHealth
Virta
Muse® by Interaxon Inc.
Uno Health
AutoCruitment
bswift
CertifyOS
Chicago Pacific Founders
DexCare
ENT Specialty Partners
Goldman Sachs
Harmony Recovery Group
Health Management Academy
ID Connect
MediaLab
MEDSIR
MyCare Medical
Nevada Behavioral Health
Ochsner Digital Health
On Belay
Oncology Care Partners
Patina Health
Press Ganey
Renalogic
Roivant/ Zest Dermatology
Spesana
Stella
Surgo Health
US Heart and Vascular
XP Health
Zenyth Partners
The Smilist
Laguna Health
Front Range Clinic
Edenbridge Health
Align ENT + Allergy
Apex Health Solutions
Veterinary Innovative Partners
SendaRide
Tailor Made Compounding
Allymar Health Solutions
Psych Hub
b.well
Home Care Delivered
Fortified Health Security
Fluent
Homebase Medical
Eon Health
NCQA
Hicuity Health
Synergy Health Partners
Inbound Health
Repose
Synapse Health
Accorded
Vytalize Health
Muir Wood
Mindoula
Women’s Care
​Sunstone Therapies
Payground
Ark Behavioral Health
Janus Health
Gratia Health
ParetoHealth
eBlu Solutions
Allergy & ENT Associates
Capital Rx
RTI Surgical
Frontier Psychiatry
MaxHealth
AnswersNow
Springbuk
Porch Light Health
PartsSource
1upHealth, Inc.
Q-Centrix
Denim Health
Circadian Health
NeuroFlow
Seminal Capital Holdings
Hello Heart
Beekman Investment Advisors
PAI Pharma
OVR Technology
CollabriOS Health
Merative
Onpoint Healthcare Partners
Kontakt.io
BC Platforms
Arkos Health
BioIntelliSense
CareNu
DocPanel
FitOn Health
GrayHawk Health
Inbox Health
ModifyHealth
Motion MSK
OpenLoop Health
Phoenix Digital Health
Point Quest Group
ReferWell
REVA
Reveleer
Rhythm Management Group
Stamford Hospital (Health)
Sunny Rewards
Tulea Health
Viz.ai
WellBe Senior Medical
Your Behavioral Health
GAM
Strive Health
Abacus Insights
Pip Care
Point C Health
DrFirst
NeoGenomics Laboratories
HME Specialists
Laudio
Population Health Partners
EarliTec Diagnostics, Inc.
Medrite
Florence Health
Patient Funding Alternatives
NextCare
Rezolut
Intuitive Health
OncoHealth
Synthpop
Knowtion Health
Druid City Vital Care
SAI Group
Fay Nutrition
Persivia
Carda Health
Katch